Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Irel…
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.69, read 2026-11-05
Ethical passes the values gate
Price44.54 USD
Fair value48.89
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-25Read Accumulation44.11+1.0% to today ✓Distribution gives way to Accumulation after a 9% rise in 2 weeks
2026-10-11Read Distribution40.54+9.9% to today Markdown gives way to Distribution after a 16% slide in 7 weeks
2026-08-21Read Markdown48.37-7.9% to today ✓Markup gives way to Markdown after a 9% rise in 7 weeks
2026-07-02Read Markup44.28+0.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Alkermes plc holds its Accumulation at $44.54. The statistical read favours the buyers, held for 128 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 128 days
Price at the screen
$44.54
Valuation
N/A trailing · 25.38 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.23
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.81%
Below 33%
Interest-bearing debt is just 2.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
8.03%
Below 33%
Cash held in interest-bearing accounts and securities is 8.0% of assets, under the one-third limit.
Pass
Receivables
26.43%
Below 49%
Money owed to the company is 26.4% of assets, under the 49% limit.
Pass
Revenue purity
3.07%
Below 5%
Only 3.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Alkermes clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ALKS's ethical verdict changes
Today ALKS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 9% discount to our $48.89 fair value, 27.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 8.9% discount to the base estimate.
Where our models see it going: fair-value estimate $48.89, with a range of $34.20 to $56.22, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Fast growing drug maker commands a premium price
A patient in need of better mental health or addiction treatments gets the medicine from Alkermes research pipeline. The company is posting 28% revenue growth and clearing the ethical screen with a clean bill. Yet the shares sit at 52.72 dollars against our 42.02 dollar fair value, a 20% stretch that leaves no margin of safety.
That valuation looks even richer next to a 32 times forward earnings multiple, a 10% profit margin and just 9% return on equity. Analyst targets cluster around 48 dollars, below where the stock trades today. Growth is real but the price already bakes in more optimism than the returns on capital can support.
High multiples on modest profitability often signal the risk of disappointment if pipeline delivery slows or competition intensifies. The business clears ethics but fails on price. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALKS trades on Nasdaq (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Accumulation$45.34+2.8%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45. Insiders have been net sellers over the past quarter.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
2026-10-18Distribution$40.10-1.1%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45. Insiders have been net sellers over the past quarter.
2026-10-02Markdown$40.54-11.8%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-09-21Markdown$45.97-5.0%Entry 7
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-08-21Markdown · changed$48.37-8.3%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-21Markup$52.72+19.1%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-18Markup$44.28+0.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-17Markup$44.28+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
